BIOMARKER:
FDA-APPROVED THERAPY:
Lynparza® (olaparib) or Rubraca® (rucaparib)
FDA-APPROVED THERAPY:
Cosmegen (Dactinomycin), Dactinomycin, Doxorubicin Hydrochloride, Eribulin Mesylate, Gleevec (Imatinib Mesylate), Halaven (Eribulin Mesylate), Imatinib Mesylate, Pazopanib Hydrochloride, Tazemetostat Hydrobromide, Tazverik (Tazemetostat Hydrobromide), Trabectedin, Votrient (Pazopanib Hydrochloride), Yondelis (Trabectedin)